Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2004033431 - HYDROXYPYRAZOLES FOR USE AGAINST METABOLIC-RELATED DISORDERS

Publication Number WO/2004/033431
Publication Date 22.04.2004
International Application No. PCT/US2003/031509
International Filing Date 02.10.2003
Chapter 2 Demand Filed 03.05.2004
IPC
C07D 401/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
CPC
C07D 401/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
Applicants
  • ARENA PHARMACEUTICALS, INC. [US]/[US] (AllExceptUS)
  • SEMPLE, Graeme [GB]/[US]
  • SHIN, Young, Jun [KR]/[US]
Inventors
  • SEMPLE, Graeme
  • SHIN, Young, Jun
Agents
  • SPRUCE, Lyle
Priority Data
60/416,19304.10.2002US
60/417,12007.10.2002US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HYDROXYPYRAZOLES FOR USE AGAINST METABOLIC-RELATED DISORDERS
(FR) HYDROXYPYRAZOLES ET METHODES PROPHYLACTIQUES OU DE TRAITEMENT DE TROUBLES LIES AU METABOLISME
Abstract
(EN) The present invention relates to certain hydroxypyrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the nicotinic acid receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of &agr;-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
(FR) La présente invention concerne certains dérivés de hydroxypyrazole de formule (I), et des sels pharmaceutiquement acceptables desdits dérivés, qui présentent des propriétés pharmaceutiques utiles, par exemple comme agonistes du récepteur de l'acide nicotinique. L'invention concerne également des compositions pharmaceutiques contenant les composés de l'invention, et des méthodes d'utilisation de ces composés et compositions pour la prophylaxie ou le traitement de troubles liés au métabolisme, y compris la dyslipidémie, l'athérosclérose, la cardiopathie coronaire, la résistance à l'insuline, le diabète non insulino-dépendant, le Syndrome X ou analogue. L'invention concerne en outre l'utilisation des composés de l'invention en association avec d'autres substances actives, telles que celles appartenant à la classe des inhibiteurs de l'?-glucosidase, des inhibiteurs de l'aldose réductase, des biguanides, des inhibiteurs de la HMG-CoA réductase, des inhibiteurs de la synthèse du squalène, des fibrates, des facteurs d'augmentation du catabolisme des LDL, des inhibiteurs de l'enzyme de conversion de l'angiotensine (ACE), des stimulateurs de sécrétion de l'insuline, et analogues.
Related patent documents
Latest bibliographic data on file with the International Bureau